ClinicalTrials.gg
CompletedNCT01263314Updated Nov 5, 2018Results posted

Safety, Tolerability, and Pharmacokinetics of MK-8266 in Elderly Participants With High Blood Pressure (MK-8266-003)

A Phase 1 interventional study of MK-8266 and Placebo in Hypertension, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 65 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-11-05.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
65 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies in Hypertension by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Hypertension · Merck & Co., Inc.

Enrollment
31st of 32
16 · median 84
Started
2010
with 5 others
Phase 1
17 of 33
none open now
Registered
22nd of 33
by date

Among the 33 studies in Hypertension by Merck & Co., Inc, this one is the 31st largest by enrollment of the 32 interventional ones that give a count, is one of 6 that started in 2010, is one of 17 in phase 1, and was the 22nd registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

None of the 33 studies in Hypertension by Merck & Co., Inc is open now. The open studies under Hypertension, anywhere →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 65 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 33 studies in Hypertension by Merck & Co., Inc as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled study. The hypothesis for this study is that single oral doses of MK-8266 selected for this study are sufficiently safe and well tolerated by elderly male and elderly female participants with hypertension to permit continued clinical investigation.

Read the detailed description

Two panels, each consisting of eight participants (8 elderly males with mild to moderate hypertension in Panel A and 8 elderly females with mild to moderate hypertension in Panel B) will be randomized to receive either MK-8266 or matching placebo in a 3:1 ratio. Participants will receive single doses of MK-8266 or matching placebo in three treatment periods (Periods 1 through 3). In both Panel A and Panel B, doses will escalate in a rising, fixed sequence. In Period 1 (0.3 mg), Period 2 (0.6 mg), and Period 3 (0.7 mg and then 0.3 mg 10 hours later) once daily doses of MK-8266 or matching placebo will be administered.

All participants will receive at least 2 doses of MK-8266. Participants completing placebo treatment in Period 1 will flow to the MK-8266 arm in the next period, with 2 participants from the MK-8266 arm receiving placebo in the next period.

Blood samples will be obtained pre-dose and at selected time points up to 48 hours post-dose for determination of MK-8266 plasma concentrations.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Hypertension
04

Who can participate

Ages eligible
65 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants are male or non-childbearing female.
  • Participant with essential hypertension (HTN), Grade 1 or 2 (as per European Society of Hypertension [ESH]) or isolated mild to moderate systolic HTN. High normal systolic BP ≥130 mmHg will be also allowed. Blood pressures to be confirmed on at least three occasions pre-study. The possibility of secondary causes of HTN should be assessed. Participants who are being treated for HTN with drugs (including beta blocking medications) may be able to participate if the drug doses can be reduced or discontinued, at the discretion of the investigator.
  • Participants with a (BMI) ≤35 kg/m\^2 at the screening visit.
  • Participants judged to be generally in good health based on medical history, physical examination, vital sign measurements (with the exception of HTN), and laboratory safety tests performed at the screening visit.
  • Participant has no abnormality (confirmed by the investigator in consultation with the Merck Clinical Monitor) on (ECG) or Holter Monitor Evaluation performed at the screening visit and/or prior to administration of the initial dose of study drug.
  • Participants must have a count ≥150,000 cu/mL at the screening and pre-study visit.
  • Participants, at screening, will have a positive Augmentation Index.
  • Participant has been a nonsmoker and/or has not used nicotine or nicotine-containing products for at least 6 months; participants who have discontinued smoking or the use of nicotine/nicotine containing products for at least 3 months may be enrolled at the discretion of the investigator.
  • Participant is willing to comply with the study restrictions.
  • Participant has a negative test for hidden blood in the stool at screening.

Exclusion criteria

Exclusion criteria:

  • Participants who have had situational depression may be enrolled in the study at the discretion of the investigator.
  • Participant has an estimated of ≤60 mL/min based on the Cockcroft-Gault equation.
  • Participant has a history of stroke, chronic seizures, or major neurological disorder.
  • Participant has a history of endocrine, gastrointestinal, cardiovascular (with the exception of HTN), hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases. Participants with a history of uncomplicated kidney stones or childhood asthma may be enrolled in the study at the discretion of the investigator.
  • Patient demonstrates low blood pressure at screening and Pre-dose Day 1 while going from a semi-recumbent to standing position.
  • Participant has a functional disability that can interfere with rising from a semi-recumbent position to the standing position.
  • Participant has any personal or family history of a bleeding or a clotting disorder.
  • Participant has a history of frequent nosebleeds.
  • Participant has a history of cancer with the exceptions of: adequately treated non-melanoma skin carcinoma or carcinoma in situ of the cervix; other which have been successfully treated >10 years prior to the screening visit, for which in the judgment of both the investigator and treating physician, appropriate follow-up has revealed no evidence of recurrence from the time of treatment through the time of the screening visit; or, participants, who, in the opinion of the study investigator, are highly unlikely to sustain a recurrence for the duration of the study.
  • Participant has a history of clinically significant cardiac disease including, but not limited to hemodynamically relevant heart valve disease (if there would be any uncertainty about the diagnosis, confirmation with an echocardiography within 3 months of screening is required), or evidence of secondary cardiac damage.
  • Participant is categorized as a class II or greater functional classification for heart failure according to the (NYHA).
  • Participant is unable to refrain from or anticipates the use of any medication, including prescription and non-prescription drugs or herbal remedies (such as St. John's Wort [Hypericum perforatum]) beginning approximately 2 weeks (or 5 half-lives) prior to administration of the initial dose of study drug, throughout the study until the post-study visit. Certain medication use may be permitted after consultation with the Merck clinical monitor.
  • Participant currently and regularly uses aspirin (including low dose) and cannot be discontinued from it from 2 weeks prior to study start or has used aspirin within 2 weeks prior to study start (and anticipates using it during the course of the study); this applies also to any pain relievers and cold or sinus remedies that have aspirin in them, and the use of anti- drugs, such as clopidogrel or dipyridamole. Chronic use of certain non-steroidal anti-inflammatory drugs (NSAIDs) such as ≥500 mg of naproxen twice a day must be also avoided beginning at least 2 weeks prior the study and until the post-study visit.
  • Participant anticipates using sildenafil (Viagra®), tadalafil (Cialis®), or Vardenafil (Levitra®).
  • Participant uses or anticipates using organic nitrate preparations (for example, nitroglycerin, isosorbide mononitrate, isosorbide dinitrate or pentaerythritol) during the course of the study.
  • Participant consumes excessive amounts of alcohol, defined as greater than 3 glasses of alcoholic beverages (1 glass is approximately equivalent to: beer [284 mL/10 ounces], wine [125 mL/4 ounces], or distilled spirits [25 mL/1 ounce]) per day. Participants that consume 4 glasses of alcoholic beverages per day may be enrolled at the discretion of the investigator.
  • Participant consumes excessive amounts, defined as greater than 6 servings (1 serving is approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, or other caffeinated beverages per day.
  • Participant has had major surgery, donated or lost 1 unit of blood (approximately 500 mL) or participated in another study within 4 weeks prior to the screening visit. The 4-week window will be derived from the date of the last study procedure (i.e., post-study, AE follow-up, etc.) in the previous study to the screening visit of the current study.
  • Participant has a history of significant multiple and/or severe allergies (including latex allergy), or has had an anaphylactic reaction or significant intolerability to prescription or non-prescription drugs or food.
  • Participant is currently a regular user of illicit drugs or has a history of drug/alcohol abuse within approximately 1 year of the screening visit.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Panel A MK-8266 0.3 mg (Elderly Males with Mild/Mod. HTN)

    MK-8266 single dose 0.3 mg

    Drug: MK-8266

  • Experimental
    Panel A MK-8266 0.6 mg (Elderly Males with Mild/Mod. HTN)

    MK-8266 single dose 0.6 mg

    Drug: MK-8266

  • Experimental
    Panel A MK-8266 0.7/0.3 mg (Elderly Males with Mild/Mod. HTN)

    MK-8266 single dose 0.7 mg and then 0.3 mg after 10 hours

    Drug: MK-8266

  • Placebo comparator
    Panel A Placebo to MK-8266 (Elderly Males with Mild/Mod. HTN)

    Placebo to MK-8266 single dose

    Drug: Placebo

  • Experimental
    Panel B MK-8266 0.3 mg (Elderly Females with Mild/Mod. HTN)

    MK-8266 single dose 0.3 mg

    Drug: MK-8266

  • Experimental
    Panel B MK-8266 0.6 mg (Elderly Females with Mild/Mod. HTN)

    MK-8266 single dose 0.6 mg

    Drug: MK-8266

  • Experimental
    Panel B MK-8266 0.7/0.3 mg (Elderly Fem. with Mild/Mod. HTN)

    MK-8266 single dose 0.7 mg and then 0.3 mg after 10 hours

    Drug: MK-8266

  • Placebo comparator
    Panel B Placebo to MK-8266 (Elderly Fem. with Mild/Mod. HTN)

    Placebo to MK-8266 single dose

    Drug: Placebo

Interventions

  • Oral capsules, 0.1 mg potency

  • DrugPlacebo

    Oral placebo capsules to match MK-8266 capsules

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs)

    An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

    Time frame: Up to 48 days

  2. Number of Participants With Abnormal Laboratory Hematology Values Reported as an AE

    An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Abnormal laboratory hematology value was any AE reported under the System Organ Class of Investigations that was related to an abnormal laboratory hematology value.

    Time frame: Up to 48 days

  3. Number of Participants With Abnormal Laboratory Chemistry Values Reported as an AE

    An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Abnormal laboratory chemistry value was any AE reported under the System Organ Class of Investigations that was related to an abnormal laboratory chemistry value.

    Time frame: Up to 48 days

  4. Number of Participants With Abnormal Laboratory Urinalysis Values Reported as an AE

    An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Abnormal laboratory urinalysis value was any AE reported under the System Organ Class of Investigations that was related to an abnormal laboratory urinalysis value.

    Time frame: Up to 37 days

  5. Change From Baseline in Systolic Blood Pressure (SBP)

    Participants rested for at least 10 minutes prior to having vital sign measurements obtained.

    Time frame: Baseline and 0 to 8 hours postdose

  6. Change From Baseline in Heart Rate

    Participants rested for at least 10 minutes prior to having vital sign measurements obtained. Heart rate measurements were obtained in the semirecumbent position and 3 sets of measurements were obtained approximately 1 minute apart.

    Time frame: Baseline and 0 to 8 hours postdose

  7. Number of Participants With Abnormal Electrocardiograms (ECG) Reported as an AE

    An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. An abnormal ECG value was any AE reported under the System Organ Classes of Investigations or Cardiac that was related to an abnormal ECG value.

    Time frame: Up to 48 days

Secondary outcomes

  1. MK-8266 Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf])

    PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. (AUC\[0-inf\]) is a measure of the mean concentration levels of drug in the plasma after the dose.

    Time frame: Period 1, 2 and 3: Predose, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours postdose.

  2. MK-8266 PK Parameter Observed Maximum (Peak) Plasma Concentration (Cmax)

    PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is a measure of the maximum amount of drug in the plasma after the dose is given.

    Time frame: Period 1, 2 and 3: Predose, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours postdose.

  3. MK-8266 PK Parameter Observed Time to Reach Cmax (Tmax)

    PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is a measure of the time to reach the maximum concentration in the plasma after the drug dose. Nominal instead of actual times are presented.

    Time frame: Period 1, 2 and 3: Predose, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours postdose.

  4. MK-8266 PK Parameter Apparent Half-Life (t1/2)

    PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. t1/2 is the time required for a given drug concentration in the plasma to decrease by 50%. Results are presented for the Harmonic Mean ± Pseudo standard deviation.

    Time frame: Period 1, 2 and 3: Predose, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours postdose.

  5. The Time Weighted Average Systolic Blood Pressure (SBP) Evaluated Over 8 Hours Post Dose (TWA[0-8hrs]) Following a Single Oral Dose of MK-8266.

    Participants rested for at least 10 minutes prior to having vital sign measurements obtained. Single dose effects on central SBP were estimated as a time-weighted average over the 8-hour post single dose observation period.

    Time frame: Up to 8 hours post dose in each dosing period (Up to 8 hours)

07

Results

Posted Nov 5, 2018

Participant flow

Period 1
Participant flow — Period 1
MilestonePanel A (Elderly Males, Mild/Moderate Hypertension) Sequence 1Panel A (Elderly Males, Mild/Moderate Hypertension) Sequence 2Panel A (Elderly Males, Mild/Moderate Hypertension) Sequence 3Panel A (Elderly Males, Mild/Moderate Hypertension) Sequence 4Panel B (Elderly Females, Mild/Moderate Hypertension) Seq. 1Panel B (Elderly Females, Mild/Moderate Hypertension) Seq. 2Panel B (Elderly Females, Mild/Moderate Hypertension) Seq. 3Panel B (Elderly Females, Mild/Moderate Hypertension) Seq. 4
Started22222222
Completed22222222
Not completed00000000
Period 2
Participant flow — Period 2
MilestonePanel A (Elderly Males, Mild/Moderate Hypertension) Sequence 1Panel A (Elderly Males, Mild/Moderate Hypertension) Sequence 2Panel A (Elderly Males, Mild/Moderate Hypertension) Sequence 3Panel A (Elderly Males, Mild/Moderate Hypertension) Sequence 4Panel B (Elderly Females, Mild/Moderate Hypertension) Seq. 1Panel B (Elderly Females, Mild/Moderate Hypertension) Seq. 2Panel B (Elderly Females, Mild/Moderate Hypertension) Seq. 3Panel B (Elderly Females, Mild/Moderate Hypertension) Seq. 4
Started22222222
Completed22222222
Not completed00000000
Period 3
Participant flow — Period 3
MilestonePanel A (Elderly Males, Mild/Moderate Hypertension) Sequence 1Panel A (Elderly Males, Mild/Moderate Hypertension) Sequence 2Panel A (Elderly Males, Mild/Moderate Hypertension) Sequence 3Panel A (Elderly Males, Mild/Moderate Hypertension) Sequence 4Panel B (Elderly Females, Mild/Moderate Hypertension) Seq. 1Panel B (Elderly Females, Mild/Moderate Hypertension) Seq. 2Panel B (Elderly Females, Mild/Moderate Hypertension) Seq. 3Panel B (Elderly Females, Mild/Moderate Hypertension) Seq. 4
Started22222222
Completed22222222
Not completed00000000

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs)

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

Time frame:
Up to 48 days
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsPanel A MK-8266 0.3 mg (Elderly Males With Mild/Moderate HTN)Panel A MK-8266 0.6 mg (Elderly Males With Mild/Moderate HTN)Panel A MK-8266 0.7 /0.3 mg (Elderly Males, Mild/Moderate HTN)Panel A Placebo to MK-8266 (Elderly Males, Mild/Moderate HTN)Panel B MK-8266 0.3 mg (Elderly Females, Mild/Moderate HTN)Panel B MK-8266 0.6 mg (Elderly Females, Mild/Moderate HTN)Panel B MK-8266 0.7/0.3 mg (Elderly Fem., Mild/Moderate HTN)Panel B Placebo to MK-8266 (Elderly Fem., Mild/Moderate HTN)
Number of Participants With Adverse Events (AEs)44315444
PrimaryNumber of Participants With Abnormal Laboratory Hematology Values Reported as an AE

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Abnormal laboratory hematology value was any AE reported under the System Organ Class of Investigations that was related to an abnormal laboratory hematology value.

Time frame:
Up to 48 days
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Laboratory Hematology Values Reported as an AE
ParticipantsPanel A MK-8266 0.3 mg (Elderly Males With Mild/Moderate HTN)Panel A MK-8266 0.6 mg (Elderly Males With Mild/Moderate HTN)Panel A MK-8266 0.7 /0.3 mg (Elderly Males, Mild/Moderate HTN)Panel A Placebo to MK-8266 (Elderly Males, Mild/Moderate HTN)Panel B MK-8266 0.3 mg (Elderly Females, Mild/Moderate HTN)Panel B MK-8266 0.6 mg (Elderly Females, Mild/Moderate HTN)Panel B MK-8266 0.7/0.3 mg (Elderly Fem., Mild/Moderate HTN)Panel B Placebo to MK-8266 (Elderly Fem., Mild/Moderate HTN)
Number of Participants With Abnormal Laboratory Hematology Values Reported as an AE00000000
PrimaryNumber of Participants With Abnormal Laboratory Chemistry Values Reported as an AE

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Abnormal laboratory chemistry value was any AE reported under the System Organ Class of Investigations that was related to an abnormal laboratory chemistry value.

Time frame:
Up to 48 days
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Laboratory Chemistry Values Reported as an AE
ParticipantsPanel A MK-8266 0.3 mg (Elderly Males With Mild/Moderate HTN)Panel A MK-8266 0.6 mg (Elderly Males With Mild/Moderate HTN)Panel A MK-8266 0.7 /0.3 mg (Elderly Males, Mild/Moderate HTN)Panel A Placebo to MK-8266 (Elderly Males, Mild/Moderate HTN)Panel B MK-8266 0.3 mg (Elderly Females, Mild/Moderate HTN)Panel B MK-8266 0.6 mg (Elderly Females, Mild/Moderate HTN)Panel B MK-8266 0.7/0.3 mg (Elderly Fem., Mild/Moderate HTN)Panel B Placebo to MK-8266 (Elderly Fem., Mild/Moderate HTN)
Number of Participants With Abnormal Laboratory Chemistry Values Reported as an AE00000000
PrimaryNumber of Participants With Abnormal Laboratory Urinalysis Values Reported as an AE

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Abnormal laboratory urinalysis value was any AE reported under the System Organ Class of Investigations that was related to an abnormal laboratory urinalysis value.

Time frame:
Up to 37 days
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Laboratory Urinalysis Values Reported as an AE
ParticipantsPanel A MK-8266 0.3 mg (Elderly Males With Mild/Moderate HTN)Panel A MK-8266 0.6 mg (Elderly Males With Mild/Moderate HTN)Panel A MK-8266 0.7 /0.3 mg (Elderly Males, Mild/Moderate HTN)Panel A Placebo to MK-8266 (Elderly Males, Mild/Moderate HTN)Panel B MK-8266 0.3 mg (Elderly Females, Mild/Moderate HTN)Panel B MK-8266 0.6 mg (Elderly Females, Mild/Moderate HTN)Panel B MK-8266 0.7/0.3 mg (Elderly Fem., Mild/Moderate HTN)Panel B Placebo to MK-8266 (Elderly Fem., Mild/Moderate HTN)
Number of Participants With Abnormal Laboratory Urinalysis Values Reported as an AE00000000
PrimaryChange From Baseline in Systolic Blood Pressure (SBP)

Participants rested for at least 10 minutes prior to having vital sign measurements obtained.

Time frame:
Baseline and 0 to 8 hours postdose
Reported as:
Least squares mean · Millimeters of mercury
Change From Baseline in Systolic Blood Pressure (SBP)
Millimeters of mercuryPanel A MK-8266 0.3 mg (Elderly Males With Mild/Mod. HTN)Panel A MK-8266 0.6 mg (Elderly Males With Mild/Mod. HTN)Panel A MK-8266 0.7 /0.3 (Elderly Males With Mild/Mod. HTN)Panel A Placebo to MK-8266 (Elderly Males Mild/Moderate HTN)Panel B MK-8266 0.3 mg (Elderly Females With Mild/Mod. HTN)Panel B MK-8266 0.6 mg (Elderly Females, Mild/Moderate HTN)Panel B MK-8266 0.7/0.3 mg (Elderly Fem., Mild/Moderate HTN)Panel B Placebo to MK-8266 (Elderly Fem., Mild/Moderate HTN)
Baseline148.3 ± 8.87137.2 ± 19.09134.0 ± 12.96132.7 ± 10.93141.7 ± 13.38139.5 ± 11.10137.7 ± 7.76142.0 ± 18.10
Change from Baseline-0.71 ± 3.85-0.79 ± 7.44-1.13 ± 4.130.54 ± 4.83-0.33 ± 10.01-4.16 ± 10.25-2.28 ± 5.875.91 ± 9.00
Statistical analysis
  • Panel A MK-8266 0.3 mg (Elderly Males With Mild/Mod. HTN) vs Panel A Placebo to MK-8266 (Elderly Males Mild/Moderate HTN) · ANOVA · p = 0.3551 · Mean difference (final values): -1.25 · 90% CI -7.01 to 4.50
  • Panel A MK-8266 0.6 mg (Elderly Males With Mild/Mod. HTN) vs Panel A Placebo to MK-8266 (Elderly Males Mild/Moderate HTN) · ANOVA · p = 0.3474 · Mean difference (final values): -1.32 · 90% CI -7.08 to 4.48
  • Panel A MK-8266 0.7 /0.3 (Elderly Males With Mild/Mod. HTN) vs Panel A Placebo to MK-8266 (Elderly Males Mild/Moderate HTN) · ANOVA · p = 0.3105 · Mean difference (final values): -1.67 · 90% CI -7.42 to 4.09
  • Panel B MK-8266 0.3 mg (Elderly Females With Mild/Mod. HTN) vs Panel B Placebo to MK-8266 (Elderly Fem., Mild/Moderate HTN) · ANOVA · p = 0.1346 · Mean difference (final values): -6.25 · 90% CI -15.8 to 3.27
  • Panel B MK-8266 0.6 mg (Elderly Females, Mild/Moderate HTN) vs Panel B Placebo to MK-8266 (Elderly Fem., Mild/Moderate HTN) · ANOVA · p = 0.0416 · Mean difference (final values): -10.1 · 90% CI -19.6 to -0.56
  • Panel B MK-8266 0.7/0.3 mg (Elderly Fem., Mild/Moderate HTN) vs Panel B Placebo to MK-8266 (Elderly Fem., Mild/Moderate HTN) · ANOVA · p = 0.0762 · Mean difference (final values): -8.20 · 90% CI -17.7 to 1.32
PrimaryChange From Baseline in Heart Rate

Participants rested for at least 10 minutes prior to having vital sign measurements obtained. Heart rate measurements were obtained in the semirecumbent position and 3 sets of measurements were obtained approximately 1 minute apart.

Time frame:
Baseline and 0 to 8 hours postdose
Reported as:
Least squares mean · Beats per minute
Change From Baseline in Heart Rate
Beats per minutePanel A MK-8266 0.3 mg (Elderly Males With Mild/Mod. HTN)Panel A MK-8266 0.6 mg (Elderly Males With Mild/Mod. HTN)Panel A MK-8266 0.7 /0.3 (Elderly Males With Mild/Mod. HTN)Panel A Placebo to MK-8266 (Elderly Males Mild/Moderate HTN)Panel B MK-8266 0.3 mg (Elderly Females With Mild/Mod. HTN)Panel B MK-8266 0.6 mg (Elderly Females, Mild/Moderate HTN)Panel B MK-8266 0.7/0.3 mg (Elderly Fem., Mild/Moderate HTN)Panel B Placebo to MK-8266 (Elderly Fem., Mild/Moderate HTN)
Baseline68.83 ± 9.2467.83 ± 10.5358.33 ± 5.5069.00 ± 8.3765.33 ± 5.3265.00 ± 5.9761.33 ± 4.2363.83 ± 5.64
Change from Baseline0.58 ± 6.124.23 ± 4.787.90 ± 4.890.11 ± 7.852.40 ± 2.375.51 ± 3.276.65 ± 3.331.25 ± 3.57
Statistical analysis
  • Panel A MK-8266 0.3 mg (Elderly Males With Mild/Mod. HTN) vs Panel A Placebo to MK-8266 (Elderly Males Mild/Moderate HTN) · ANOVA · p = 0.418 · Mean difference (final values): 0.47 · 90% CI -3.47 to 4.41
  • Panel A MK-8266 0.6 mg (Elderly Males With Mild/Mod. HTN) vs Panel A Placebo to MK-8266 (Elderly Males Mild/Moderate HTN) · ANOVA · p = 0.0434 · Mean difference (final values): 4.12 · 90% CI 0.18 to 8.05
  • Panel A MK-8266 0.7 /0.3 (Elderly Males With Mild/Mod. HTN) vs Panel A Placebo to MK-8266 (Elderly Males Mild/Moderate HTN) · ANOVA · p = 0.0019 · Mean difference (final values): 7.79 · 90% CI 3.85 to 11.72
  • Panel B MK-8266 0.3 mg (Elderly Females With Mild/Mod. HTN) vs Panel B Placebo to MK-8266 (Elderly Fem., Mild/Moderate HTN) · ANOVA · p = 0.2223 · Mean difference (final values): 1.15 · 90% CI -1.42 to 3.71
  • Panel B MK-8266 0.6 mg (Elderly Females, Mild/Moderate HTN) vs Panel B Placebo to MK-8266 (Elderly Fem., Mild/Moderate HTN) · ANOVA · p = 0.0056 · Mean difference (final values): 4.25 · 90% CI 1.69 to 6.82
  • Panel B MK-8266 0.7/0.3 mg (Elderly Fem., Mild/Moderate HTN) vs Panel B Placebo to MK-8266 (Elderly Fem., Mild/Moderate HTN) · ANOVA · p = 0.0012 · Mean difference (final values): 5.40 · 90% CI 2.83 to 7.96
PrimaryNumber of Participants With Abnormal Electrocardiograms (ECG) Reported as an AE

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. An abnormal ECG value was any AE reported under the System Organ Classes of Investigations or Cardiac that was related to an abnormal ECG value.

Time frame:
Up to 48 days
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Electrocardiograms (ECG) Reported as an AE
ParticipantsPanel A MK-8266 0.3 mg (Elderly Males With Mild/Moderate HTN)Panel A MK-8266 0.6 mg (Elderly Males With Mild/Moderate HTN)Panel A MK-8266 0.7 /0.3 mg (Elderly Males, Mild/Moderate HTN)Panel A Placebo to MK-8266 (Elderly Males, Mild/Moderate HTN)Panel B MK-8266 0.3 mg (Elderly Females, Mild/Moderate HTN)Panel B MK-8266 0.6 mg (Elderly Females, Mild/Moderate HTN)Panel B MK-8266 0.7/0.3 mg (Elderly Fem., Mild/Moderate HTN)Panel B Placebo to MK-8266 (Elderly Fem., Mild/Moderate HTN)
Number of Participants With Abnormal Electrocardiograms (ECG) Reported as an AE00000000
SecondaryMK-8266 Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf])

PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. (AUC\[0-inf\]) is a measure of the mean concentration levels of drug in the plasma after the dose.

Time frame:
Period 1, 2 and 3: Predose, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours postdose.
Reported as:
Mean · nM•hr
MK-8266 Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf])
nM•hrPanel A MK-8266 0.3 mg (Elderly Males With Mild/Moderate HTN)Panel A MK-8266 0.6 mg (Elderly Males With Mild/Moderate HTN)Panel A MK-8266 0.7 /0.3 mg (Elderly Males, Mild/Moderate HTN)Panel A Placebo to MK-8266 (Elderly Males, Mild/Moderate HTN)Panel B MK-8266 0.3 mg (Elderly Females, Mild/Moderate HTN)Panel B MK-8266 0.6 mg (Elderly Females, Mild/Moderate HTN)Panel B MK-8266 0.7/0.3 mg (Elderly Fem., Mild/Moderate HTN)Panel B Placebo to MK-8266 (Elderly Fem., Mild/Moderate HTN)
MK-8266 Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf])—208 ± 81.5314 ± 108——247 ± 66.8449 ± 130—
Statistical analysis
  • Panel A MK-8266 0.6 mg (Elderly Males With Mild/Moderate HTN) vs Panel B MK-8266 0.6 mg (Elderly Females, Mild/Moderate HTN) · Gmr (elderly female/elderly male): 1.23 · 90% CI 0.85 to 1.76GMR = geometric mean ratio
SecondaryMK-8266 PK Parameter Observed Maximum (Peak) Plasma Concentration (Cmax)

PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is a measure of the maximum amount of drug in the plasma after the dose is given.

Time frame:
Period 1, 2 and 3: Predose, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours postdose.
Reported as:
Mean · ng/mL
MK-8266 PK Parameter Observed Maximum (Peak) Plasma Concentration (Cmax)
ng/mLPanel A MK-8266 0.3 mg (Elderly Males With Mild/Moderate HTN)Panel A MK-8266 0.6 mg (Elderly Males With Mild/Moderate HTN)Panel A MK-8266 0.7 /0.3 mg (Elderly Males, Mild/Moderate HTN)Panel A Placebo to MK-8266 (Elderly Males, Mild/Moderate HTN)Panel B MK-8266 0.3 mg (Elderly Females, Mild/Moderate HTN)Panel B MK-8266 0.6 mg (Elderly Females, Mild/Moderate HTN)Panel B MK-8266 0.7/0.3 mg (Elderly Fem., Mild/Moderate HTN)Panel B Placebo to MK-8266 (Elderly Fem., Mild/Moderate HTN)
MK-8266 PK Parameter Observed Maximum (Peak) Plasma Concentration (Cmax)7.76 ± 2.2514.1 ± 3.4516.2 ± 4.13—7.84 ± 1.8017.8 ± 2.5219.5 ± 2.61—
Statistical analysis
  • Panel A MK-8266 0.3 mg (Elderly Males With Mild/Moderate HTN) vs Panel B MK-8266 0.3 mg (Elderly Females, Mild/Moderate HTN) · Gmr (elderly female/elderly male): 1.08 · 90% CI 0.88 to 1.33
  • Panel A MK-8266 0.6 mg (Elderly Males With Mild/Moderate HTN) vs Panel B MK-8266 0.6 mg (Elderly Females, Mild/Moderate HTN) · Gmr (elderly female/elderly male): 1.26 · 90% CI 1.02 to 1.55
  • Panel A MK-8266 0.7 /0.3 mg (Elderly Males, Mild/Moderate HTN) vs Panel B MK-8266 0.7/0.3 mg (Elderly Fem., Mild/Moderate HTN) · Gmr (elderly female/elderly male): 1.20 · 90% CI 0.98 to 1.48
SecondaryMK-8266 PK Parameter Observed Time to Reach Cmax (Tmax)

PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is a measure of the time to reach the maximum concentration in the plasma after the drug dose. Nominal instead of actual times are presented.

Time frame:
Period 1, 2 and 3: Predose, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours postdose.
Reported as:
Median · Hours
MK-8266 PK Parameter Observed Time to Reach Cmax (Tmax)
HoursPanel A MK-8266 0.3 mg (Elderly Males With Mild/Moderate HTN)Panel A MK-8266 0.6 mg (Elderly Males With Mild/Moderate HTN)Panel A MK-8266 0.7 /0.3 mg (Elderly Males, Mild/Moderate HTN)Panel A Placebo to MK-8266 (Elderly Males, Mild/Moderate HTN)Panel B MK-8266 0.3 mg (Elderly Females, Mild/Moderate HTN)Panel B MK-8266 0.6 mg (Elderly Females, Mild/Moderate HTN)Panel B MK-8266 0.7/0.3 mg (Elderly Fem., Mild/Moderate HTN)Panel B Placebo to MK-8266 (Elderly Fem., Mild/Moderate HTN)
MK-8266 PK Parameter Observed Time to Reach Cmax (Tmax)2.0 (1.5 to 4.0)2.0 (1.5 to 3.0)2.0 (2.0 to 3.0)—4.0 (2.0 to 6.0)3.5 (2.0 to 4.0)4.0 (3.0 to 12)—
SecondaryMK-8266 PK Parameter Apparent Half-Life (t1/2)

PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. t1/2 is the time required for a given drug concentration in the plasma to decrease by 50%. Results are presented for the Harmonic Mean ± Pseudo standard deviation.

Time frame:
Period 1, 2 and 3: Predose, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours postdose.
Reported as:
Mean · Hours
MK-8266 PK Parameter Apparent Half-Life (t1/2)
HoursPanel A MK-8266 0.3 mg (Elderly Males With Mild/Moderate HTN)Panel A MK-8266 0.6 mg (Elderly Males With Mild/Moderate HTN)Panel A MK-8266 0.7 /0.3 mg (Elderly Males, Mild/Moderate HTN)Panel A Placebo to MK-8266 (Elderly Males, Mild/Moderate HTN)Panel B MK-8266 0.3 mg (Elderly Females, Mild/Moderate HTN)Panel B MK-8266 0.6 mg (Elderly Females, Mild/Moderate HTN)Panel B MK-8266 0.7/0.3 mg (Elderly Fem., Mild/Moderate HTN)Panel B Placebo to MK-8266 (Elderly Fem., Mild/Moderate HTN)
MK-8266 PK Parameter Apparent Half-Life (t1/2)—12.7 ± 4.814.3 ± 3.8——13.6 ± 4.515.4 ± 3.4—
SecondaryThe Time Weighted Average Systolic Blood Pressure (SBP) Evaluated Over 8 Hours Post Dose (TWA[0-8hrs]) Following a Single Oral Dose of MK-8266.

Participants rested for at least 10 minutes prior to having vital sign measurements obtained. Single dose effects on central SBP were estimated as a time-weighted average over the 8-hour post single dose observation period.

Time frame:
Up to 8 hours post dose in each dosing period (Up to 8 hours)
Reported as:
Least squares mean · millimeters of mercury
The Time Weighted Average Systolic Blood Pressure (SBP) Evaluated Over 8 Hours Post Dose (TWA[0-8hrs]) Following a Single Oral Dose of MK-8266.
millimeters of mercuryPanel A MK-8266 0.3 mg (Elderly Males With Mild/Moderate HTN)Panel A MK-8266 0.6 mg (Elderly Males With Mild/Moderate HTN)Panel A MK-8266 0.7 /0.3 mg (Elderly Males, Mild/Moderate HTN)Panel A Placebo to MK-8266 (Elderly Males, Mild/Moderate HTN)Panel B MK-8266 0.3 mg (Elderly Females, Mild/Moderate HTN)Panel B MK-8266 0.6 mg (Elderly Females, Mild/Moderate HTN)Panel B MK-8266 0.7/0.3 mg (Elderly Fem., Mild/Moderate HTN)Panel B Placebo to MK-8266 (Elderly Fem., Mild/Moderate HTN)
The Time Weighted Average Systolic Blood Pressure (SBP) Evaluated Over 8 Hours Post Dose (TWA[0-8hrs]) Following a Single Oral Dose of MK-8266.146.4 ± 11.73134.2 ± 12.96132.7 ± 12.34136.8 ± 8.61142.4 ± 13.19135.0 ± 8.22136.0 ± 6.82146.6 ± 12.54
Statistical analysis
  • Panel A MK-8266 0.3 mg (Elderly Males With Mild/Moderate HTN) vs Panel A Placebo to MK-8266 (Elderly Males, Mild/Moderate HTN) · ANOVA · p = 0.0253 · Mk-8266 0.3 mg vs. placebo: 9.58 · 90% CI 1.69 to 17.46
  • Panel A MK-8266 0.6 mg (Elderly Males With Mild/Moderate HTN) vs Panel A Placebo to MK-8266 (Elderly Males, Mild/Moderate HTN) · ANOVA · p = 0.2856 · Mk-8266 0.6 mg vs. placebo: -2.59 · 90% CI -10.5 to 5.29
  • Panel A MK-8266 0.7 /0.3 mg (Elderly Males, Mild/Moderate HTN) vs Panel A Placebo to MK-8266 (Elderly Males, Mild/Moderate HTN) · ANOVA · p = 0.1895 · Mk-8266 0.7 mg/ 0.3 mg vs. placebo: -4.06 · 90% CI -11.9 to 3.82
  • Panel B MK-8266 0.3 mg (Elderly Females, Mild/Moderate HTN) vs Panel B Placebo to MK-8266 (Elderly Fem., Mild/Moderate HTN) · ANOVA · p = 0.1157 · Mk-8266 0.3 mg vs. placebo: -4.16 · 90% CI -10.0 to 1.70
  • Panel B MK-8266 0.6 mg (Elderly Females, Mild/Moderate HTN) vs Panel B Placebo to MK-8266 (Elderly Fem., Mild/Moderate HTN) · ANOVA · p = 0.0018 · Mk-8266 0.6 mg vs. placebo: -11.7 · 90% CI -17.5 to -5.79
  • Panel B MK-8266 0.7/0.3 mg (Elderly Fem., Mild/Moderate HTN) vs Panel B Placebo to MK-8266 (Elderly Fem., Mild/Moderate HTN) · ANOVA · p = 0.0034 · Mk-8266 0.7 mg/ 0.3 mg vs. placebo: -10.6 · 90% CI -16.5 to -4.77

Adverse events

Collected over Up to 48 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Panel A MK-8266 0.3 mg (Elderly Males With Mild/Moderate HTN)0/6 (0%)0/6 (0%)4/6 (66.7%)
Panel A MK-8266 0.6 mg (Elderly Males With Mild/Moderate HTN)0/6 (0%)0/6 (0%)4/6 (66.7%)
Panel A MK-8266 0.7 /0.3 mg (Elderly Males, Mild/Moderate HTN)0/6 (0%)0/6 (0%)3/6 (50%)
Panel A Placebo to MK-8266 (Elderly Males, Mild/Moderate HTN)0/6 (0%)0/6 (0%)1/6 (16.7%)
Panel B MK-8266 0.3 mg (Elderly Females, Mild/Moderate HTN)0/6 (0%)0/6 (0%)5/6 (83.3%)
Panel B MK-8266 0.6 mg (Elderly Females, Mild/Moderate HTN)0/6 (0%)0/6 (0%)4/6 (66.7%)
Panel B MK-8266 0.7/0.3 mg (Elderly Fem., Mild/Moderate HTN)0/6 (0%)0/6 (0%)4/6 (66.7%)
Panel B Placebo to MK-8266 (Elderly Fem., Mild/Moderate HTN)0/6 (0%)0/6 (0%)4/6 (66.7%)
Most frequent other events
Showing 10 of 21
Most frequent other events
EventPanel A MK-8266 0.3 mg (Elderly Males With Mild/Moderate HTN)Panel A MK-8266 0.6 mg (Elderly Males With Mild/Moderate HTN)Panel A MK-8266 0.7 /0.3 mg (Elderly Males, Mild/Moderate HTN)Panel A Placebo to MK-8266 (Elderly Males, Mild/Moderate HTN)Panel B MK-8266 0.3 mg (Elderly Females, Mild/Moderate HTN)Panel B MK-8266 0.6 mg (Elderly Females, Mild/Moderate HTN)Panel B MK-8266 0.7/0.3 mg (Elderly Fem., Mild/Moderate HTN)Panel B Placebo to MK-8266 (Elderly Fem., Mild/Moderate HTN)
HeadacheNervous system disorders2/62/61/60/61/63/61/62/6
NasopharyngitisInfections and infestations0/60/60/60/60/60/62/60/6
Blood pressure systolic increasedInvestigations2/60/60/60/61/60/61/61/6
Skin irritationSkin and subcutaneous tissue disorders0/60/60/60/62/60/60/60/6
Abdominal discomfortGastrointestinal disorders0/60/60/60/60/61/60/60/6
Abdominal painGastrointestinal disorders0/60/60/60/60/60/61/60/6
DiarrhoeaGastrointestinal disorders0/60/61/60/61/61/61/60/6
Faeces hardGastrointestinal disorders1/60/60/60/60/60/60/60/6
NauseaGastrointestinal disorders0/60/60/60/60/61/60/60/6
VomitingGastrointestinal disorders0/60/60/60/60/61/60/61/6

Baseline characteristics

Baseline characteristics for all participants receiving study treatment. Participants are grouped according to either Panel A or Panel B (i.e. males or females with mild/moderate hypertension).

Age, Continuous
Age, Continuous(Years)Panel A (Elderly Males, Mild/Moderate Hypertension)Panel B (Elderly Females, Mild/Moderate Hypertension)Total
Mean68.0 ± 2.868.9 ± 2.868.4 ± 2.7
Sex: Female, Male
Sex: Female, Male(Participants)Panel A (Elderly Males, Mild/Moderate Hypertension)Panel B (Elderly Females, Mild/Moderate Hypertension)Total
Female088
Male808
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2010 to primary completion in Feb 2011, 3 months.

Results were first posted in Nov 2018, 7 years 9 months after primary completion.

Of 132 industry-sponsored phase 1 interventional studies under Hypertension, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 3 months is above that.

Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 1 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2010
First posted
Dec 20, 2010
StartActual
Nov 1, 2010
Primary completionActual
Feb 1, 2011
CompletionActual
Mar 1, 2011
Results first posted
Nov 5, 2018
Last update
Nov 5, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 5, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01263314
Responsible party
Sponsor
First posted
Dec 20, 2010
Start date
Nov 1, 2010
Primary completion
Feb 1, 2011
Completion
Mar 1, 2011
Results posted
Nov 5, 2018
Last update
Nov 5, 2018

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MK-8266

Start the discussion